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IntrOductIOn
Dipyridamole is a nucleoside transport inhibitor that augments 
endogenous adenosine [1]. Moreover, it inhibits phosphodiesterases 
and causes an increase in cellular content of cyclic Adenosine 
Monophosphate (cAMP) and cyclic guanosine monophosphate 
(cGMP) [2]. Dipyridamole is indicated for the induction of stress in 
myocardial scintigraphy [3].
Adenosine plays an important role as a paracrine and/
or an autocrine  hormone  in a variety of physiological or 
pathophysiological processes including cardiovascular diseases 
and diabetes [4,5]. It acts by binding to adenosine receptors 
and influences glucose disposal, carbohydrate metabolism, 
lipolysis and insulin sensitivity [6,7], local blood flow [8], mean 
arterial pressure and heart rate [9]. Four adenosine receptors 
(A1, A2a, A2b, and A3) have been cloned and characterized in 
mammalian species. While A1 and A3 receptors are preferentially 
coupled to inhibitory G-proteins (Gi/o), the A2 receptors interact 
with stimulatory G-protein (Gs) [10]. Adenosine A3 receptors 
were found to produce cardioprotective effects during myocardial 
ischemia/ischemic reperfusion [10]. On the other hand, blockade 
of adenosine A1 receptors improves glucose tolerance in obese 
Zucker rats; these rats show a better profile of peak serum insulin 
level and areas under glucose curves, compared to untreated 
rats [11]. Yet, adenosine is not the sole mediator of dipyridamole 
pharmacological effects [12]. 
It is noteworthy that the concentration of dipyridamole required 
to produce a significant effect on glycolytic rate (2µM) is much 
 
less than that required to exert a significant rise in intracellular 
and interstitial adenosine concentration in muscles (50µM) [12]. 
Dipyridamole reduces glucose-induced osteopontin expression 
in arterial vasculature, thereby decreasing the medial artery 
calcification and stiffness. This effect is mediated through inhibition 
of phosphodiesterase, and Reactive Oxygen Species (ROS) [2]. 
However, a net effect of dipyridamole in blood sugar during cardiac 
scintigraphy has been not investigated. 
Cardiovascular stress test using exercise or pharmacological 
agents has long been established as a diagnostic procedure 
in cardiovascular scintigraphy. In this regard, pharmacological 
stress is produced by dobutamine, dipyridamole, adenosine or 
regadenoson [13]. Dipyridamole inhibits intracellular reuptake and 
deamination of adenosine, thereby producing a vasodilatory effect 
on coronary arteries. Such an effect on coronary vasodilation 
is attenuated in diseased coronary arteries, showing a reduced 
coronary flow reserve and failure of dilation in response to the drug 
[14]. 
The aim of this study was to evaluate the acute effect of 
dipyridamole on blood glucose in patients undergoing myocardial 
rest/stress scintigraphy using 99mTc-sestamibi. In addition, a 
potential alteration of the outcome of a radionuclide scan was 
explored.
MAterIAls And MethOds
This cross-sectional study was performed on 299 patients who 
were recruited from the Department of Nuclear Medicine of 
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ABstrAct
Introduction: Dipyridamole inhibits adenosine reuptake and 
increases cyclic Adenosine Monophosphate (cAMP) levels 
in platelets, erythrocytes and endothelial cells, all of which 
influence blood glucose. Acute hyperglycaemia reduces 
endothelium-dependent vasodilation and suppresses coronary 
microcirculation; which, in theory, can alter the outcome of a 
radionuclide scan. 
Aim: The present study was conducted with the aim to 
investigate the changes in blood glucose level of patients 
receiving dipyridamole for cardiac scan. 
Materials and Methods: A total of 293 patients (85 men and 
208 women, age: 60.59±10.43 years) were included in the study. 
Fasting Blood Glucose (FBG) was measured before and 8 min 
after dipyridamole (0.568 mg/kg) injection during myocardial 
perfusion imaging. The data in different groups were analysed 
by paired t-test. 
results: There was not a significant difference between first 
(106.89 ± 19.21mg/dL) and second (107.98 ± 17.57 mg/dL) 
FBG measurements (p= 0.293). However, when the patients 
were grouped based on the quartiles of first measurement, 
there was an increase in FBG following dipyridamole injection in 
the first quartile (mean difference: 7.15±21.27 mg/dL, p<0.01); 
in contrast, FBG levels showed a significant decrease after 
dipyridamole administration in the 4th quartile (mean difference: 
-9.53±18.20 mg/dL, p<0.001). The differences in 2nd and 3rd 
quartiles were negligible. The patients were divided into normal, 
ischemic and fixed lesions based on the outcome of scans, 
then the possible correlation of dipyridamole-induced FBG 
alteration and scan results were investigated. There were no 
significant difference between the FBG values before and after 
dipyridamole injection and the final outcome of scan. 
conclusion: The effects of dipyridamole on blood glucose 
highly depend on the initial blood glucose level. 
www.jcdr.net Amirreza Khorasanchi et al., Dipyridamole on BS
Journal of Clinical and Diagnostic Research. 2016 Aug, Vol-10(8): TC24-TC27 25
 
Keywords: Blood glucose, Dipyridamole, Myocardial perfusion imaging
paired differences of fbG (mg/dl)
group fbG (mg/dl) mean 
difference
Sd Sem 95%ci of the difference t df Sig. (2-tailed)
before 
dipyridamole
After 
dipyridamole
lower upper
FBG1_Q1 89.35 96.50 7.15 21.27 2.52 2.12 12.19 2.83 70.00 0.01*
FBG1_Q2 101.03 99.56 -1.47 11.67 1.36 -4.18 1.23 -1.09 73.00 0.28
FBG1_Q3 110.62 110.44 -0.18 12.70 1.48 -3.12 2.77 -0.12 73.00 0.91
FBG1_Q4 130.16 120.63 -9.53 18.20 2.12 -13.74 -5.31 -4.50 73.00 0.001*
Total 107.98 106.89 -1.09 17.33 1.01 -3.08 0.90 -1.08 292.00 0.28
[table/Fig-2]: Difference between FBG values before and after dipyridamole administration when the patients were grouped based on the quartile of the first FBG 
measurement.
Fasting blood glucose (FBG) *statistically significant
paired differences of fbG (mg/dl)
fbG (mg/dl) mean 
difference
Sd Sem 95% ci of the difference t df Sig. (2-tailed)
before 
dipyridamole
After 
dipyridamole
lower upper
FBG1<126 103.68 104.12 0.44 15.78 0.98 -1.48 2.36 0.45 261.00 0.65
FBG1>126 144.35 130.32 -14.03 23.73 4.26 -22.74 -5.33 -3.29 30.00 0.001*
[table/Fig-3]: Difference between FBG values before and after dipyridamole administration when the patients were grouped into diabetic and non-diabetic according to first 
FBG.
Fasting blood glucose (FBG) *statistically significant
n fbG (mg/dl)
mean Sem Sd minimum maximum
FBG1_Q1 71.00 89.35 0.77 6.48 61.00 96.00
FBG1_Q2 74.00 101.03 0.29 2.50 97.00 105.00
FBG1_Q3 74.00 110.62 0.31 2.70 106.00 115.00
FBG1_Q4 74.00 130.16 1.98 17.00 116.00 197.00
Total 293.00 107.98 1.03 17.57 61.00 197.00
[table/Fig-1]: Division of the patients based on the quartiles of the 1st FBG values 
(mg/dl).
Fasting blood glucose (FBG), Q: quartiles
analysed by paired t-test. Spearman test was used to explore 
the correlation between FBG values and the final outcome of the 
scan. The p-values of less than 0.05 were considered statistically 
significant.
results
FBG was measured before and 8min after dipyridamole 
administration. There was not a significant difference in FBG 
values before (106.89 ± 19.21 mg/dL) and after (107.98 ± 17.57 
mg/dL) dipyridamole administration (p= 0.293). The patients were 
then divided into four groups based on the values of first FBG 
measurement [Table/Fig-1], and the difference between FBG 
values before and after dipyridamole was analysed in quartiles. 
We observed an increase in FBG following dipyridamole injection 
in the first quartile (mean difference: 7.15±21.27 mg/dL, p<0.01); 
in contrast, FBG levels showed a significant decrease after 
dipyridamole administration in the 4th quartile (mean difference: 
-9.53±18.20 mg/dL, p<0.001). The difference in the 2nd(-
1.47±11.67 mg/dL, p=0.28) and the 3rd (-0.18±12.70 mg/dL, 
p=0.91) quartiles were negligible [Table/Fig-2]. In addition, FBG 
levels before and after dipyridamole did not show a significant 
difference in non-diabetic patients (1st FBG<126), whereas there 
were a significant decrease in FBG levels (mean difference: 
-14.03± 23.73 mg/dL, p< 0.01) after dipyridamole administration 
in diabetic patients (1st FBG>126 mg/dL, [Table/Fig-3]). 
The patients were divided into normal, ischemic and fixed lesions 
based on the outcome of scans. We then sought the possible 
correlation between the scan outcome and FBG values. There were 
not a significant correlation between the scan outcome and FBG 
values before (rho: 0.07, p=0.24) and after (rho: 0.037, p=0.53) 
dipyridamole administration, nor between the scan outcome and 
the dipyridamole-induced alteration of FBG value before and after 
dipyridamole (rho: -0.01, p=0.855). 
dIscussIOn 
Dipyridamole is a nucleoside transport inhibitor that augments 
endogenous adenosine and increases cellular content of cyclic 
neucleosides [1]. Dipyridamole produces a 44% increase in 
coronary blood flow as well as a 32% decrease in coronary vascular 
resistance. Moreover, dipyridamole increases glucose uptake 
by 5 times and ATP content by 11%. In contrast, it decreases 
lactate uptake by 97% and does not significantly alter ADP or AMP 
content of the myocardial tissue [17].
Shahroud University of Medical Sciences for about two years, 
starting in early 2013. Six patients were excluded from the study 
because of severe hypoglycaemia. The patients (85 men and 208 
women, age: 60.59±10.43 years) were instructed to discontinue 
all cardiovascular medications 48h before the scan, and to fast 
overnight. Fasting Blood Glucose (FBG) was measured before and 
8min after dipyridamole (0.568mg/kg) injection [15]. The study was 
conducted under a protocol approved by ethics committee of the 
Shahroud University of Medical Sciences. Furthermore, either the 
patients or their parents signed a consent form.
Acquisition Protocol 
Technetium-99m metaiodobenzylisonitril (99mTc-MIBI) in a dose of 
740MBq was injected intravenously (i.v.) and was administered 
4min after dipyridamole injection, and gated single photon emission 
computed tomography (SPECT) was conducted 90min later, 
the patient being in the supine position. All patients underwent 
a rest-stress scan using a dual-head -camera (GE Healthcare) in 
90° setting, equipped with high-resolution, low-energy (HRLE) 
collimators. Sixty-four views (25sec per view) over 180° (from 45° 
right anterior oblique to 45° left posterior oblique) were obtained 
with a zoom factor of 1.45 and gated at 8 frames per cardiac cycle 
using an R-wave trigger and stored in a 64×64 matrix [16]. The 
patients were then grouped as normal perfusion scan, ischemic 
scans and fixed scans. 
stAtIstIcAl AnAlysIs
The  distribution of variables was checked using probability 
plots and the Shapiro-Wilk test and they were fit to a gaussian 
distribution. The data are represented as mean ± Standard 
Deviation (SD). The potential difference between FBG values 
before or after dipyridamole injection as well as their quartiles was 
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We observed a significant decrease in FBG levels after dipyridamole 
administration (0.568 mg/kg) in 4th quartile (mean difference: 
-9.53±18.20 mg/dL, p<0.001). Adenosine mediated increase of 
blood flow enhances glucose and insulin delivery to the active 
muscle fibers. In addition, activation of A1-adenosine receptors 
directly stimulates insulin-mediated glucose uptake in oxidative 
muscle cells [8]. However, hypoxia-induced muscle glucose uptake 
does not seem to be influenced by adenosine receptors [5,18]. 
Blockade of adenosine receptors by 8-phenyltheophylline (8-PTH) 
inhibits insulin-induced myocardial glucose uptake [19]. In this 
regard, an increase in plasma glucose in diabetic rats augments 
the expression of adenosine A1 receptor in the liver, highlighting 
the possible contribution of these receptors to glucose-lowering 
effects in diabetic rats lacking insulin [20]. Chronic administration 
of low dose dipyridamole (20mg/kg, 4 weeks) had no effect on the 
elevated glucose levels in streptozotocin-induced diabetic rats. 
However, it decreased structural and functional abnormalities in 
the kidney [21]. Dipyridamole (0.568mg/kg) consistently enhances 
myocardial glucose uptake in areas with diminished vasodilatory 
capacity of coronary arteries as demonstrated by fluorine-18-
fluorodeoxyglucose positron emission tomography (18F-FDG 
PET) [22]. Furthermore, intravenous injections of dipyridamole or 
N6-cyclopentyladenosine (CPA, Adenosine A1 receptor agonist) 
decrease plasma glucose in fasting streptozocine-diabetic rats in a 
dose-dependent manner [23]. Moreover, CPA augments glycogen 
synthesis in isolated soleus muscle [23]. Adenosine A2a receptor 
agonist, 5'-N-ethylcarboxamidoadenosine (NECA), is also shown 
to enhance beta cell regeneration and accelerate restoration 
of normoglycaemia in zebrafish [24]. It can also reduce serum 
glucose in diabetic mice [24]. Inhibition of phosphodiestrases by 
dipyridamole is also demonstrated to causes an increase in cAMP 
content of the cell; thereby activating the guanine nucleotide 
exchange factor activated by cAMP (Epac2) and protein kinase 
A (PKA). These intracellular molecules are reported to be involved 
in the stimulation of insulin exocytosis [25]. The above mentioned 
evidences indicate a possible role for adenosine and cyclic 
neucleosides in glucose-lowering effects of dipyridamole.
In contrast to the upper quartile (FBG: 116-197 mg/dL), we 
found an increase in FBG following dipyridamole injection in first 
quartile (FBG: 61-96 mg/dL; mean difference: 7.15±21.27 mg/dL, 
p<0.01). Dipyridamole (50mg/kg) mitigates endotoxin-mediated 
decrease in blood glucose and liver cAMP content in mice [26]. 
Translocation of  Glucose Transporter GLUT4 from intracellular 
stores to the sarcolemma mediates the insulin or contraction-
induced glucose uptake cardiac myocytes [27]. In adipocytes and 
L6 muscle cell lines, the glucose transport inhibitor, dipyridamole, 
binds with higher affinity to GLUT4 than to GLUT1 [24,25]. 
However, it does not seem to influence subcellular distribution 
of GLUT4 or glucose uptake in cardiac myocytes [27]. On the 
other hand, Shuralyova et al., demonstrated a dose-dependent 
inhibition of both basal and insulin-stimulated glucose transport 
by dipyridamole (basal, IC50 = 12.2µM, insulin stimulated, IC50 = 
13.09µM) in HL-1 cardiomyocytes. This effect is more likely to be 
mediated through pathways other than the inhibition of adenosine 
reuptake [28]. These observations may explain the proischemic 
effects of dipyridamole at high doses [29] as well as a significant 
rise of FBG following dipyridamole administration in 1st quartile 
(FBG: 61-96 mg/dL) in this study. 
Acute hyperglycaemia reduces endothelium-dependent vasodi-
lation and suppresses coronary microcirculation. Williams et al., 
investigated the endothelium-dependent vasodilation through 
brachial artery infusion of methacholine before and during intra-
arterial infusion Dextrose 50% for 6h they observed a significant 
reduction  of  forearm  blood  flow after local hyperglycaemia 
(300 mg/dL) in healthy subjects, indicating the impairment of 
endothelium-dependent vasodilation during acute hyperglycaemia 
in vivo [30]. Similarly, Fujimoto et al., reported a significant decline in 
coronary flow velocity reserve 1 hour after acute oral glucose loading 
(4.4±0.7 vs. 3.8±0.7 cm/sec, respectively) using transthoracic 
Doppler echocardiography in healthy men. This result suggests 
that acute hyperglycaemia may have adverse effects on coronary 
microcirculation [31]. There was not a significant correlation between 
the scan outcome and FBG values before (rho: 0.064, p=0.273) 
and after (rho: 0.04, p=0.486) dipyridamole administration, nor 
between the scan outcome and dipyridamole-induced changes in 
blood glucose (rho: -0.001, p=0.982). In this regard, Capaldo et al., 
investigated the effects of acute hyperglycaemia on coronary flow 
reserve (the ratio of dipyridamole/resting coronary peak diastolic 
flow velocity) in healthy volunteers using transthoracic colour 
Doppler echocardiography. They found a substantial increase in 
coronary flow velocity after dipyridamole infusion. However, acute 
hyperglycaemia (glucose and octreotide (0.4mg/h) infusion for 3h 
to reach an approximate glucose concentration of 252 mg/dL and 
stable plasma insulin) did not seem to influence the vasodilatory 
response of coronary microcirculation [32]. 
lIMItAtIOn 
In this study, the effects of dipyridamole on blood glucose was 
investigated, yet it lacks a control group with exercise stress. It is 
reported that moderate or high –intensity exercise can influence 
blood glucose in healthy or diabetic patients. This study showed 
significant alteration of blood glucose by dipyridamole in patients 
with FBG less than 96 or above 116 mg/dL. Future studies with 
both pharmacological and exercise stress are required for accurate 
conclusion. 
cOnclusIOn
Dipyridamole may increase, decrease, or not influence blood 
glucose depending on its initial level. However, these changes in 
blood glucose do not seem to be correlated with final outcome of 
the scan. 
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